Literature DB >> 23794600

An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides.

Pei Tong1, Zhifeng Lu, Xi Chen, Qian Wang, Fei Yu, Peng Zou, Xiaoxia Yu, Yu Li, Lu Lu, Ying-Hua Chen, Shibo Jiang.   

Abstract

OBJECTIVES: We previously constructed a trimeric coiled coil, N28Fd, based on the N-heptad repeat (NHR) sequence of HIV-1 gp41, as a promising HIV-1 entry inhibitor. Here, we attempted to engineer a stabilized trimeric coiled coil, ccN28Fd, by adding interchain disulphide bonds at the N terminus of N28Fd to improve its biophysical properties and anti-HIV-1 efficacy.
METHODS: Molecular biology techniques were applied to engineer ccN28Fd. Circular dichroism and sedimentation velocity analysis were used to determine its secondary structure and thermostability and polymeric states, respectively. The anti-HIV-1 activity was assessed by p24 or luciferase expression. Its cytotoxicity was evaluated by XTT assay.
RESULTS: At low pH, ccN28Fd and N28Fd were in trimeric and monomeric conformation, respectively. ccN28Fd showed higher thermostability and much stronger antiviral activity against HIV-1 IIIB (X4) and Bal (R5) strains than N28Fd. ccN28Fd was effective in inhibiting infection by a broad spectrum of primary HIV-1 isolates and enfuvirtide-resistant strains and blocking cell-to-cell HIV-1 transmission. A combination of ccN28Fd with tenofovir, a nucleoside reverse transcriptase inhibitor-based microbicide, exhibited potent synergistic anti-HIV-1 activity. ccN28Fd was highly resistant to digestion by proteinase K at pH 7.2 and pepsin at pH 1.5, and its anti-HIV-1 activity was not significantly affected by the presence of hydroxyethyl cellulose gel, seminal fluid or vaginal fluid simulant. It possessed no significant in vitro cytotoxicity.
CONCLUSIONS: The engineered ccN28Fd maintains high stability in a low pH environment and exhibits potent and broad anti-HIV-1 activity, suggesting good potential for development as an effective and safe vaginal microbicide to prevent HIV sexual transmission.

Entities:  

Keywords:  N-heptad repeat; disulphide bonds; enfuvirtide; tenofovir; trimer

Mesh:

Substances:

Year:  2013        PMID: 23794600     DOI: 10.1093/jac/dkt230

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.

Authors:  Qian Wang; Wenwen Bi; Xiaojie Zhu; Haoyang Li; Qianqian Qi; Fei Yu; Lu Lu; Shibo Jiang
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

2.  Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.

Authors:  Sara Crespillo; Ana Cámara-Artigas; Salvador Casares; Bertrand Morel; Eva S Cobos; Pedro L Mateo; Nicolas Mouz; Christophe E Martin; Marie G Roger; Raphaelle El Habib; Bin Su; Christiane Moog; Francisco Conejero-Lara
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

3.  Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.

Authors:  Shan Su; Yun Zhu; Sheng Ye; Qianqian Qi; Shuai Xia; Zhenxuan Ma; Fei Yu; Qian Wang; Rongguang Zhang; Shibo Jiang; Lu Lu
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

4.  Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.

Authors:  Gita N Shankar; Carsten Alt
Journal:  J Antimicrob Chemother       Date:  2014-08-19       Impact factor: 5.790

Review 5.  Peptide-Based Dual HIV and Coronavirus Entry Inhibitors.

Authors:  Huan Wang; Chao Wang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses.

Authors:  Yufeng Yu; Yong-Qiang Deng; Peng Zou; Qian Wang; Yanyan Dai; Fei Yu; Lanying Du; Na-Na Zhang; Min Tian; Jia-Nan Hao; Yu Meng; Yuan Li; Xiaohui Zhou; Jasper Fuk-Woo Chan; Kwok-Yung Yuen; Cheng-Feng Qin; Shibo Jiang; Lu Lu
Journal:  Nat Commun       Date:  2017-07-25       Impact factor: 14.919

7.  The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1.

Authors:  Yue Tan; Pei Tong; Junyi Wang; Lei Zhao; Jing Li; Yang Yu; Ying-Hua Chen; Ji Wang
Journal:  Front Immunol       Date:  2017-04-24       Impact factor: 7.561

8.  Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.

Authors:  Xiaojie Zhu; Yun Zhu; Sheng Ye; Qian Wang; Wei Xu; Shan Su; Zhiwu Sun; Fei Yu; Qi Liu; Chao Wang; Tianhong Zhang; Zhenqing Zhang; Xiaoyan Zhang; Jianqing Xu; Lanying Du; Keliang Liu; Lu Lu; Rongguang Zhang; Shibo Jiang
Journal:  Sci Rep       Date:  2015-08-19       Impact factor: 4.379

9.  Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection.

Authors:  Chao Wang; Xue Li; Fei Yu; Lu Lu; Xifeng Jiang; Xiaoyu Xu; Huixin Wang; Wenqing Lai; Tianhong Zhang; Zhenqing Zhang; Ling Ye; Shibo Jiang; Keliang Liu
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

10.  Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations.

Authors:  Yun Zhu; Shan Su; Lili Qin; Qian Wang; Lei Shi; Zhenxuan Ma; Jianchao Tang; Shibo Jiang; Lu Lu; Sheng Ye; Rongguang Zhang
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.